Study guide
8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole)
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole)
Key Takeaways Explain This Topic AI
Salicylate poisoning causes an early primary respiratory alkalosis via direct medullary stimulation, paired with a primary high anion gap metabolic acidosis from uncoupling of mitochondrial oxidative phosphorylation.
Systemic acidemia protonates salicylic acid into a non-ionized lipophilic form that readily crosses the blood-brain barrier; maintaining systemic and urine alkalinization (urine pH 7.5–8.0) traps salicylate ions in the renal tubules, accelerating clearance 10- to 20-fold.
Hypokalemia prevents urinary alkalinization by forcing renal tubular H+/K+ ATPase to reabsorb potassium while secreting protons into the urine; potassium must be proactively maintained at 4.0–4.5 mEq/L (adding 20–40 mEq KCl/L).
EXTRIP (2015) recommends hemodialysis for salicylate concentrations above 100 mg/dL (above 90 mg/dL with impaired kidney function), altered mental status, new hypoxemia needing oxygen, or failure of standard therapy, and suggests it at above 90 mg/dL (above 80 with impaired kidney function) or pH 7.20 or lower.
Toxic alcohols produce metabolic acidosis with elevated anion and osmolar gaps: ethylene glycol produces glycolic and oxalic acids (calcium oxalate nephrolithiasis/AKI), while methanol generates formic acid (optic neuropathy and putaminal necrosis); fomepizole (15 mg/kg load) competitively inhibits ADH, supplemented by thiamine/pyridoxine for ethylene glycol and leucovorin for methanol.
Last updated: October 2026
8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole)
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around clinical toxicology and emergency medicine pharmacotherapy principles.
Salicylate Toxicity: Pathophysiology & Acid-Base Dynamics
Salicylate poisoning (acetylsalicylic acid, aspirin) presents one of the most intellectually rigorous diagnostic and management challenges in clinical emergency toxicology. Salicylates disrupt cellular respiration across multiple organ systems, creating complex mixed acid-base abnormalities. SALICYLATE DUAL ACID-BASE MECHANISM
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ 1. DIRECT MEDULLARY RESPIRATORY CENTER STIMULATION │
- │ • Salicylates directly stimulate the brainstem respiratory center │
- │ • Increases respiratory rate and tidal volume (hyperpnea/tachypnea) │
- │ • Marked washout of CO2 ──> PRIMARY RESPIRATORY ALKALOSIS │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ 2. MITOCHONDRIAL UNCOUPLING OF OXIDATIVE PHOSPHORYLATION │
- │ • Collapses the electrochemical proton gradient across inner membrane │
- │ • Halts ATP synthesis; energy is dissipated as heat (HYPERTHERMIA) │
- │ • Anaerobic glycolysis surges ──> Lactic Acid accumulation │
- │ • Impairs Krebs cycle dehydrogenases & enhances lipolysis ──> Ketoacids │
- │ • Net Result ──> PRIMARY HIGH ANION GAP METABOLIC ACIDOSIS │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ CLASSIC ADULT PRESENTATION: MIXED RESPIRATORY ALKALOSIS & METABOLIC ACIDOSIS│
- └─────────────────────────────────────────────────────────────────────────────┘
- The Physics of Ion Trapping & Central Nervous System Penetration
Salicylic acid is a weak monocarboxylic acid with an acid dissociation constant ( p K a pK_a p K a ) of 3.0 to 3.5 . In aqueous solution, it exists in an equilibrium between its non-ionized, lipophilic protonated form ( H A HA H A ) and its charged, polar conjugate base anion ( A − A^- A − ):
HA ⇌ H + + A − \text{HA} \rightleftharpoons \text{H}^+ + \text{A}^- HA ⇌ H + + A −
pH = p K a + log ( [ A − ] [ H A ] ) \text{pH} = pK_a + \log\left(\frac{[A^-]}{[HA]}\right) pH = p K a + lo g ( [ H A ] [ A − ] )
In Acidemia (Low Blood pH) : Le Chatelier's principle dictates that high extracellular hydrogen ion concentrations drive the reaction to the left, increasing the fraction of uncharged, non-ionized salicylic acid ( H A HA H A ). Non-ionized molecules readily cross lipid bilayers, including the blood-brain barrier .
CNS Neuroglycopenia & Cerebral Edema : Once inside neurons, salicylates uncouple oxidative phosphorylation, impairing glucose transport and cellular ATP production. This causes localized neuroglycopenia (intracellular cerebral glucose starvation despite normal systemic serum glucose), cerebral edema, seizures, coma, and herniation.
In Alkalemia (High Blood pH) : Raising the systemic pH shifts the equilibrium toward the charged salicylate anion ( A − A^- A − ). Polar ions cannot cross the blood-brain barrier. Systemic alkalinization draws salicylate molecules out of the central nervous system and traps them within the intravascular compartment.
Clinical Presentation
Early Manifestations : Tinnitus (often the earliest symptom, caused by uncoupling in the microvasculature of the stria vascularis in the inner ear), vertigo, diaphoresis, nausea, vomiting, tachypnea, and hyperpnea.
Severe Toxicity : Hyperthermia (poor prognostic sign indicating profound mitochondrial uncoupling), agitation, delirium, lethargy, non-cardiogenic pulmonary edema (due to increased pulmonary capillary permeability), acute kidney injury, and cardiovascular collapse.
Urinary Alkalinization & Mandatory Potassium Repletion
Urinary alkalinization is the primary emergency department elimination therapy for moderate to severe salicylate poisoning that does not meet hemodialysis criteria.
Mechanism of Enhanced Renal Elimination
Salicylate is freely filtered at the glomerulus and reabsorbed along the proximal and distal convoluted tubules via passive non-ionic diffusion. Under acidic urinary conditions, salicylate remains non-ionized and is passively reabsorbed back into peritubular capillaries. When the urine is alkalinized to a pH of 7.5 to 8.0 :
Filtered salicylic acid in the tubular lumen is deprotonated into polar salicylate anions ( A − A^- A − ).
Charged salicylate ions cannot traverse the lipid-rich tubular epithelium.
Salicylate is effectively trapped in the lumen and excreted in the urine.
Raising urine pH from 5.0 to 8.0 increases renal salicylate clearance by 10- to 20-fold!
Urinary Alkalinization Protocol
Infusion Composition : 100 to 150 mEq of Sodium Bicarbonate (2 to 3 ampules of 8.4% NaHCO 3 \text{NaHCO}_3 NaHCO 3 ) mixed in 1,000 mL of 5% Dextrose in Water (D5W).
Infusion Rate : Administer at 1.5 to 2 times the maintenance fluid rate (typically 150 to 250 mL/h in adults).
Target Parameters :
Urine pH : Maintain between 7.5 and 8.0 (measure every void or hourly via Foley catheter).
Blood / Arterial pH : Maintain between 7.45 and 7.55 .
Safety Limit : Never permit systemic arterial pH to exceed 7.55 to 7.60 . Extreme alkalemia precipitates hypocalcemic tetany, profound hypokalemia, cerebral vasoconstriction, and malignant dysrhythmias.
The Potassium Trap: Mandatory Potassium Repletion
Caution
Hypokalemia is the single most frequent cause of failed urinary alkalinization. You cannot alkalinize the urine in a hypokalemic patient. THE HYPOKALEMIC PARADOXICAL ACIDURIA TRAP
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ In Hypokalemia: │
- │ 1. Cortical collecting duct alpha-intercalated cells attempt to conserve │
- │ potassium via the apical H+/K+ ATPase pump │
- │ 2. To reabsorb one K+ ion, the pump MUST SECRETE ONE H+ ION into urine │
- │ 3. Net Result: PARADOXICAL ACIDURIA (Urine pH < 6.0) │
- │ 4. Bicarbonate infusion fails to alkalinize tubular fluid; salicylate │
- │ remains non-ionized and reabsorbs into circulation │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ CLINICAL MANDATE: Proactively add 20–40 mEq KCl per liter of bicarbonate │
- │ infusion to maintain serum potassium at 4.0–4.5 mEq/L. │
- └─────────────────────────────────────────────────────────────────────────────┘
- Indications for Emergent Hemodialysis in Salicylate Toxicity
Salicylates possess ideal physicochemical properties for extracorporeal removal: low molecular weight (138 Da), low volume of distribution ( V d ≈ 0.15 – 0.2 L/kg V_d \approx 0.15–0.2\text{ L/kg} V d ≈ 0.15–0.2 L/kg ), and decreased plasma protein binding (which falls from 90% at therapeutic levels to < 50 % <50\% < 50% in severe toxicity). Intermittent hemodialysis rapidly clears salicylate, corrects refractory acid-base disorders, and restores volume equilibrium.
EXTRIP Workgroup Consensus Indications
The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup's 2015 salicylate recommendations do not separate acute from chronic poisoning. Older teaching used a lower threshold (about 60 mg/dL) for chronic toxicity, but EXTRIP relies on concentration, kidney function and clinical features. Intermittent hemodialysis is preferred:
Clinical / Laboratory Criterion Threshold & Rationale
Salicylate Concentration (recommended) > 100 mg/dL >100\text{ mg/dL} > 100 mg/dL ( > 7.2 mmol/L >7.2\text{ mmol/L} > 7.2 mmol/L ) , or > 90 mg/dL >90\text{ mg/dL} > 90 mg/dL ( > 6.5 mmol/L >6.5\text{ mmol/L} > 6.5 mmol/L ) with impaired kidney function
Salicylate Concentration (suggested) > 90 mg/dL >90\text{ mg/dL} > 90 mg/dL , or > 80 mg/dL >80\text{ mg/dL} > 80 mg/dL with impaired kidney function
Central Nervous System Toxicity Altered mental status, coma, encephalopathy, cerebral edema, or seizures (reflects toxic neuroglycopenia).
New Hypoxemia Requiring Supplemental Oxygen Usually non-cardiogenic pulmonary edema; bicarbonate fluids worsen it, while HD removes drug and controls volume (recommended).
Acute Kidney Injury / Oliguria AKI eliminates renal clearance pathways, rendering urinary alkalinization ineffective.
Severe Acidemia Systemic pH ≤ 7.20 \le 7.20 ≤ 7.20 (suggested).
Failure of Standard Therapy Worsening clinical status or rising salicylate concentrations despite optimal alkalinization (recommended).
Toxic Alcohols: Ethylene Glycol vs. Methanol
Ingestion of toxic alcohols constitutes an immediate, life-threatening metabolic emergency. While parent alcohols produce modest inebriation, their oxidized hepatic metabolites generate devastating systemic toxicity. TOXIC ALCOHOL METABOLISM
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ ETHYLENE GLYCOL: │
- │ Ethylene Glycol ──(Alcohol Dehydrogenase)──> Glycoaldehyde │
- │ Glycoaldehyde ──(Aldehyde Dehydrogenase)───> Glycolic Acid (Acidosis) │
- │ Glycolic Acid ─────────────────────────────> Glyoxylic Acid │
- │ Glyoxylic Acid ──(Thiamine/Pyridoxine)─────> α-Hydroxy-ketoadipate/Glycine│
- │ Glyoxylic Acid ──(Oxidation)───────────────> Oxalic Acid │
- │ └─> Binds Ca2+ ──> Calcium Oxalate Monohydrate Crystals (AKI & ATN) │
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ METHANOL: │
- │ Methanol ──(Alcohol Dehydrogenase)─────────> Formaldehyde │
- │ Formaldehyde ──(Aldehyde Dehydrogenase)────> Formic Acid (Formate) │
- │ Formic Acid ──(Folate / Leucovorin Pathway)─> CO2 + H2O │
- │ └─> Inhibits Cytochrome Oxidase ───────> Optic Neuritis / Blindness, │
- │ Basal Ganglia / Putaminal Nec│
- └─────────────────────────────────────────────────────────────────────────────┘
- Toxic Alcohol Comparison Matrix
Parameter Ethylene Glycol Methanol
Common Sources Engine coolants, automotive antifreeze, de-icing solutions, industrial solvents. Windshield washer fluids, gas line de-icers, canned cooking fuels (Sterno), illicit bootleg alcohol.
Primary Toxic Metabolite Glycolic acid (causes profound metabolic acidosis); Oxalic acid (tissue precipitation). Formic acid (formate) (inhibits mitochondrial cytochrome c oxidase; histotoxic cellular hypoxia).
Target Organ Injury Kidneys : Acute tubular necrosis, calcium oxalate crystal deposition, acute oliguric renal failure. Eyes : Retinal ganglion cell toxicity, optic disk hyperemia, permanent blindness; Brain : Putaminal necrosis.
Pathognomonic Signs Envelope- or needle-shaped calcium oxalate monohydrate crystals in urine; Wood's lamp fluorescence of urine (fluorescein additive). Visual blurring, scotomata, 'snowstorm' vision , photophobia, dilated non-reactive pupils, parkinsonism.
Electrolyte Anomalies Severe Hypocalcemia (calcium consumed during oxalate precipitation), QTc prolongation, tetany. Profound anion gap metabolic acidosis; normal calcium levels.
Osmolar Gap & Anion Gap Dynamics
Calculated Serum Osmolarity : Calculated Osmolarity = 2 [ Na + ] + [ Glucose ] 18 + [ BUN ] 2.8 + [ Ethanol ] 4.6 \text{Calculated Osmolarity} = 2[\text{Na}^+] + \frac{[\text{Glucose}]}{18} + \frac{[\text{BUN}]}{2.8} + \frac{[\text{Ethanol}]}{4.6} Calculated Osmolarity = 2 [ Na + ] + 18 [ Glucose ] + 2.8 [ BUN ] + 4.6 [ Ethanol ]
Osmolar Gap : Osmolar Gap = Measured Osmolality (Freezing Point) − Calculated Osmolarity \text{Osmolar Gap} = \text{Measured Osmolality (Freezing Point)} - \text{Calculated Osmolarity} Osmolar Gap = Measured Osmolality (Freezing Point) − Calculated Osmolarity
The Diagnostic Gap Timeline : A normal osmolar gap is < 10 mOsm/kg <10\text{ mOsm/kg} < 10 mOsm/kg . An osmolar gap > 20 mOsm/kg >20\text{ mOsm/kg} > 20 mOsm/kg strongly suggests the presence of an unmeasured toxic alcohol.
Early Post-Ingestion : Parent alcohols are low-molecular-weight, osmotically active particles. Initially, the osmolar gap is markedly elevated , while the anion gap is completely normal.
Late Post-Ingestion : As alcohol dehydrogenase metabolizes parent molecules into charged organic acids (glycolate or formate), the osmolar gap closes while the high anion gap metabolic acidosis widens .
Warning
Never rule out a toxic alcohol ingestion based on a normal osmolar gap in a patient presenting late with an unexplained high anion gap metabolic acidosis. The parent alcohol may have already been completely metabolized into toxic acid.
Antidote Therapy: Fomepizole vs. Ethanol
Definitive antidote therapy for toxic alcohol ingestion centers on blocking the initial rate-limiting enzyme: Alcohol Dehydrogenase (ADH) .
Fomepizole (4-Methylpyrazole, 4-MP)
Fomepizole is the preferred, first-line antidote for both ethylene glycol and methanol poisonings.
Mechanism : Potent competitive inhibitor of ADH with an affinity for the enzyme approximately 8,000 times greater than that of ethanol.
Standard Dosing Regimen :
Loading Dose : 15 mg/kg IV administered as an infusion over 30 minutes.
Maintenance Dosing : 10 mg/kg IV every 12 hours for 4 doses.
Auto-induction Adjustment : After 48 hours of continuous therapy, fomepizole induces its own hepatic CYP450 metabolism; the maintenance dose must be increased to 15 mg/kg IV every 12 hours until toxic alcohol levels clear.
Hemodialysis Dosing Adjustment : Fomepizole is a small molecule that is cleared by hemodialysis. During intermittent hemodialysis, the dosing interval must be shortened to every 4 hours , or administered as a continuous infusion of 1 to 1.5 mg/kg/hour.
Discontinuation Endpoints : Continue fomepizole until the ethylene glycol or methanol concentration is < 20 – 30 mg/dL <20–30\text{ mg/dL} < 20–30 mg/dL , the anion gap normalizes, and systemic acid-base balance is restored.
Ethanol Therapy (Second-Line Alternative)
When fomepizole is unavailable, pharmaceutical-grade intravenous or oral ethanol can be utilized:
Mechanism : Competes with toxic alcohols for ADH; ADH exhibits approximately 10-fold higher affinity for ethanol than for ethylene glycol or methanol.
Target Blood Level : Maintain blood ethanol concentration at 100 to 150 mg/dL (22 to 33 mmol/L).
Complications : Intravenous ethanol therapy is notoriously hazardous, requiring complex loading and maintenance calculations, frequent blood glucose and ethanol monitoring, and carries severe risks of central nervous system depression, respiratory arrest, phlebitis, and catastrophic hypoglycemia (especially in pediatric patients due to inhibition of gluconeogenesis).
Adjunctive Metabolic Cofactor Therapy
Cofactors do not inhibit ADH; rather, they drive alternative, non-toxic metabolic pathways to accelerate the elimination of downstream metabolites:
1. Methanol Cofactors
Leucovorin (Folinic Acid) or Folic Acid : 50 mg IV every 4 hours .
Mechanism : Formic acid is metabolized by the enzyme 10-formyl tetrahydrofolate dehydrogenase. Folate cofactors enhance the tetrahydrofolate pathway, accelerating the conversion of toxic formic acid into non-toxic carbon dioxide and water.
2. Ethylene Glycol Cofactors
Thiamine (Vitamin B1) : 100 mg IV every 6 hours .
Mechanism : Acts as a vital cofactor with the enzyme alpha-hydroxy-beta-ketoadipate synthase to convert glyoxylic acid into non-toxic alpha-hydroxy-beta-ketoadipate.
Pyridoxine (Vitamin B6) : 50 mg IV every 6 hours .
Mechanism : Acts as a transaminase cofactor converting glyoxylic acid into the non-toxic amino acid glycine.
Synergy : Together, thiamine and pyridoxine divert glyoxylic acid away from oxalic acid formation, directly mitigating calcium oxalate crystal deposition in the renal parenchyma.